Literature DB >> 30545830

B-cell lymphomas present immunoglobulin neoantigens.

Michael S Khodadoust1, Niclas Olsson2, Binbin Chen1,3, Brian Sworder1, Tanaya Shree1, Chih Long Liu1, Lichao Zhang2, Debra K Czerwinski1, Mark M Davis4,5, Ronald Levy1, Joshua E Elias2, Ash A Alizadeh1,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30545830      PMCID： PMC6384186          DOI： 10.1182/blood-2018-06-845156

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  30 in total

1.  Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.

Authors:  A Trojan; J L Schultze; M Witzens; R H Vonderheide; M Ladetto; J W Donovan; J G Gribben
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Synthetic peptides and beta-chain gene rearrangements reveal a diversified T cell repertoire for a lambda light chain third hypervariable region.

Authors:  B Bogen; R Snodgrass; J P Briand; K Hannestad
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

3.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

4.  CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.

Authors:  B Jahrsdörfer; G Hartmann; E Racila; W Jackson; L Mühlenhoff; G Meinhardt; S Endres; B K Link; A M Krieg; G J Weiner
Journal:  J Leukoc Biol       Date:  2001-01       Impact factor: 4.962

5.  Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain.

Authors:  Guo Xiaoling; Liu Ying; Liu Jing; Li Huifang; Zhu Xia; Fan Qingqing; Zhu Ping
Journal:  Cancer Immunol Immunother       Date:  2005-05-12       Impact factor: 6.968

6.  Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Authors:  Ronald Levy; Kristen N Ganjoo; John P Leonard; Julie M Vose; Ian W Flinn; Richard F Ambinder; Joseph M Connors; Neil L Berinstein; Andrew R Belch; Nancy L Bartlett; Craig Nichols; Christos E Emmanouilides; John M Timmerman; Stephanie A Gregory; Brian K Link; David J Inwards; Arnold S Freedman; Jeffrey V Matous; Michael J Robertson; Lori A Kunkel; Diane E Ingolia; Andrew J Gentles; Chih Long Liu; Robert Tibshirani; Ash A Alizadeh; Dan W Denney
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

7.  HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Authors:  Daniel J Kowalewski; Heiko Schuster; Linus Backert; Claudia Berlin; Stefan Kahn; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanovic; Juliane Sarah Stickel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

8.  Class II MHC self-antigen presentation in human B and T lymphocytes.

Authors:  Cristina Maria Costantino; Eric Spooner; Hidde L Ploegh; David A Hafler
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

Review 9.  Frequency Patterns of T-Cell Exposed Amino Acid Motifs in Immunoglobulin Heavy Chain Peptides Presented by MHCs.

Authors:  Robert D Bremel; E Jane Homan
Journal:  Front Immunol       Date:  2014-10-28       Impact factor: 7.561

10.  Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.

Authors:  Michael S Khodadoust; Niclas Olsson; Lisa E Wagar; Ole A W Haabeth; Binbin Chen; Kavya Swaminathan; Keith Rawson; Chih Long Liu; David Steiner; Peder Lund; Samhita Rao; Lichao Zhang; Caleb Marceau; Henning Stehr; Aaron M Newman; Debra K Czerwinski; Victoria E H Carlton; Martin Moorhead; Malek Faham; Holbrook E Kohrt; Jan Carette; Michael R Green; Mark M Davis; Ronald Levy; Joshua E Elias; Ash A Alizadeh
Journal:  Nature       Date:  2017-03-22       Impact factor: 49.962
View more
  15 in total

Review 1.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Intratumoral immunotherapy relies on B and T cell collaboration.

Authors:  Idit Sagiv-Barfi; Debra K Czerwinski; Tanaya Shree; Julian J K Lohmeyer; Ronald Levy
Journal:  Sci Immunol       Date:  2022-05-27

3.  Therapeutic vaccines for aggressive B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ken H Young
Journal:  Leuk Lymphoma       Date:  2020-08-25

4.  Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.

Authors:  Patrizia Mondello; Saber Tadros; Ari M Melnick; Michael R Green; Matt Teater; Lorena Fontan; Aaron Y Chang; Neeraj Jain; Haopeng Yang; Shailbala Singh; Hsia-Yuan Ying; Chi-Shuen Chu; Man Chun John Ma; Eneda Toska; Stefan Alig; Matthew Durant; Elisa de Stanchina; Sreejoyee Ghosh; Anja Mottok; Loretta Nastoupil; Sattva S Neelapu; Oliver Weigert; Giorgio Inghirami; José Baselga; Anas Younes; Cassian Yee; Ahmet Dogan; David A Scheinberg; Robert G Roeder
Journal:  Cancer Discov       Date:  2020-01-08       Impact factor: 38.272

Review 5.  HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Samantha M Y Chen; Zhangguo Chen; Jing H Wang
Journal:  Protein Cell       Date:  2020-03-11       Impact factor: 14.870

Review 6.  Best practices for bioinformatic characterization of neoantigens for clinical utility.

Authors:  Megan M Richters; Huiming Xia; Katie M Campbell; William E Gillanders; Obi L Griffith; Malachi Griffith
Journal:  Genome Med       Date:  2019-08-28       Impact factor: 11.117

7.  CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid.

Authors:  Rune A Høglund; Robert D Bremel; E Jane Homan; Silje Bøen Torsetnes; Andreas Lossius; Trygve Holmøy
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561

Review 8.  Neoantigens in Hematologic Malignancies.

Authors:  Melinda A Biernacki; Marie Bleakley
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

9.  Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.

Authors:  Zijun Y Xu-Monette; Jianyong Li; Yi Xia; Beryl Crossley; Robert D Bremel; Yi Miao; Min Xiao; Thomas Snyder; Ganiraju C Manyam; Xiaohong Tan; Hongwei Zhang; Carlo Visco; Alexandar Tzankov; Karen Dybkaer; Govind Bhagat; Wayne Tam; Hua You; Eric D Hsi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Miguel A Piris; Jane N Winter; Jeffrey T Medeiros; Bing Xu; Yong Li; Ilan Kirsch; Ken H Young
Journal:  J Immunother Cancer       Date:  2019-10-22       Impact factor: 13.751

10.  Human Cysteine Cathepsins Degrade Immunoglobulin G In Vitro in a Predictable Manner.

Authors:  Rune Alexander Høglund; Silje Bøen Torsetnes; Andreas Lossius; Bjarne Bogen; E Jane Homan; Robert Bremel; Trygve Holmøy
Journal:  Int J Mol Sci       Date:  2019-09-29       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.